Form 4: Revolution Medicines COO Sells Shares for Tax Obligations

Revolution Medicines' Chief Operating Officer, Margaret A. Horn, reported a future sale of 4,583 common shares to cover tax withholding obligations related to RSU vesting.

Summary

• Margaret A. Horn, Chief Operating Officer of Revolution Medicines, Inc. (RVMD), reported a planned sale of 4,583 shares of common stock.
• The transaction is scheduled for March 17, 2026, at a price of $99.4804 per share.
• This sale is pursuant to a Rule 10b5-1 plan established on May 31, 2023, specifically to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following this transaction, Ms. Horn will beneficially own 157,570 shares, which includes 73,050 Restricted Stock Units (RSUs).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. While it's an insider sale, its pre-planned nature and stated purpose for tax obligations mitigate any negative sentiment typically associated with insider selling.

Positives

• The sale is pre-planned under a Rule 10b5-1 plan, indicating it is not a discretionary sale based on new, non-public information.
• The purpose of the sale is explicitly stated as satisfying tax withholding obligations, which is a common and routine reason for insider sales.

Negatives

• An insider sale, even for tax purposes, reduces the direct equity stake of a key executive in the company.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding purposes, especially when pre-arranged under a 10b5-1 plan, are a routine occurrence and generally do not signal a change in management's confidence in the company's future. This is a common practice across the biotechnology and pharmaceutical sectors for executives receiving equity compensation.

Comparison to Industry Standards

• This type of insider transaction, specifically for tax withholding related to RSU vesting, is standard practice across publicly traded companies, including peers in the biotechnology sector such as Amgen (AMGN) or Gilead Sciences (GILD).
• It is not indicative of a unique company-specific issue or a negative outlook compared to industry benchmarks.

Stakeholder Impact

• Shareholders: Minor reduction in direct insider ownership, but the pre-planned nature for tax purposes suggests no change in fundamental company outlook.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled insider sale by the Chief Operating Officer to cover tax obligations related to RSU vesting. Such transactions are common and generally do not reflect a change in the executive's confidence in the company's prospects or fundamental performance. Therefore, it provides no new information that would warrant a change in investment recommendation based solely on this filing.

Keywords

Revolution Medicines, RVMD, Form 4, Insider Trading, Stock Sale, Margaret Horn, Chief Operating Officer, 10b5-1 Plan, RSU Vesting, Tax Withholding, Biotechnology, Pharmaceuticals